P&G earnings
This article was originally published in The Tan Sheet
Executive Summary
Prilosec OTC (omeprazole magnesium) helped drive Procter & Gamble's Health Care unit second-quarter net sales up 29% over the year-ago quarter to $2.64 bil., the firm announces Jan. 27. The healthcare segment, which was also boosted by Rx osteoporosis treatment Actonel, contributed significantly to the firm's 8% increase in organic sales for the quarter ended Dec. 31. Net sales for the period increased 27% to $18.34 bil., reflecting the Gillette acquisition completed in October. Despite Prilosec OTC's recent success, potential competitors are lining up. Novartis has licensed the switch rights toPrevacid (lansoprazole) from TAP and is eying a 2009 switch. Prilosec OTC will lose Hatch/Waxman marketing exclusivity in June, although patents listed in FDA's Orange Book extend through 2019. FDA cleared a suitability petition in July that opens the door for an ANDA application to market a generic version of Prilosec OTC in capsule form...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.